The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2023 | T-cell bispecifics in AML: ongoing challenges and future outlooks
Marion Subklewe, MD, Ludwig-Maximilians University, Munich, Germany, shares some insights into the current status of T-cell bispecific antibodies in the treatment of acute myeloid leukemia (AML). Prof. Subklewe discusses major challenges with implementing these agents in clinical practice, including the issue of identifying suitable target antigens, overcoming T-cell exhaustion, and the presence of dysfunctional T-cells in AML. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
